Addressing HPV vaccine misconceptions: insights for healthcare professionals

Human papillomavirus (HPV) vaccination remains a critical tool in preventing cervical and other types of cancer; however, its uptake is significantly lower than other adolescent vaccines. In 2017, only 66% of adolescents received their first dose of the HPV vaccine, compared to 89% for the tetanus, diphtheria, and acellular pertussis vaccine. This disparity is largely due to persistent myths and misconceptions about the HPV vaccine's safety and effectiveness.

This review tackles five prevalent myths that contribute to vaccine hesitancy. The myths include doubts about the vaccine's cancer prevention capabilities, the necessity of the vaccine given natural infection clearance, and safety concerns, among others. For example, it's clarified that while HPV vaccines were initially tested against pre-cancer endpoints rather than direct cancer outcomes, the prevention of these pre-cancers directly contributes to cancer prevention. 

Additionally, the safety of the HPV vaccine has been confirmed through extensive post-licensure surveillance, showing no significant risk of serious adverse effects. The aim of this review is to equip healthcare providers with factual, evidence-based responses to enhance discussions with patients and counteract prevalent misinformation, thereby improving HPV vaccination rates.